IL-33 regulates the IgA-microbiota axis to restrain IL-1a-dependent colitis and tumorigenesis

Journal of Clinical Investigation

Volumn 126, Issue 12, 2016, Pages 4469-4481

  Malik, Ankit ^a   Sharma, Deepika ^a   Zhu, Qifan ^a,b   Karki, Rajendra ^a   Guy, Clifford S ^a   Vogel, Peter ^a   Kanneganti, Thirumala Devi ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; INTERLEUKIN 1ALPHA; INTERLEUKIN 33; IL33 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER MORTALITY; CARCINOGENESIS; COLITIS; COLITIS ASSOCIATED CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE COURSE; EMBRYO; GENE MUTATION; HOMEOSTASIS; IMMUNOGLOBULIN PRODUCTION; INCIDENCE; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; CHEMICALLY INDUCED; GENETICS; IMMUNOLOGY; INTESTINE TUMOR; KNOCKOUT MOUSE; PATHOLOGY;

ANIMALS; COLITIS; GASTROINTESTINAL MICROBIOME; IMMUNOGLOBULIN A; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1ALPHA; INTERLEUKIN-33; INTESTINAL NEOPLASMS; MICE; MICE, KNOCKOUT;

EID: 85002926045     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI88625     Document Type: Article

References (65)

1. Kappelman MD, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gas-troenterol Hepatol. 2007;5(12):1424-1429.
2. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commer-cially insured US population. Dig Dis Sci. 2013;58(2):519-525.
3. Podolsky DK, Isselbacher KJ. Glycoprotein composition of colonic mucosa. Specific alterations in ulcerative colitis. Gastroenterology. 1984;87(5):991-998.
4. Rhodes JM. Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Lancet. 1996;347(8993):40-44.
5. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3(7):521-533.
6. Grivennikov SI, Greten FR, Karin M. Immu-nity, Inflammation, and Cancer. Cell. 2010;140(6):883-899.
7. Howlader N, et al., eds. SEER Cancer Statistics Review, 1975-2013, National Cancer Insti-tute. NIH Web site http://seer.cancer.gov/csr/1975-2013/. Updated September 12, 2016. Accessed September 19, 2016.
8. Pichery M, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol. 2012;188(7):3488-3495.
9. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA. 2009;106(22):9021-9026.
10. Lüthi AU, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic cas-pases. Immunity. 2009;31(1):84-98.
11. Louten J, et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol. 2011;23(5):307-315.
12. Barlow JL, et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol. 2012;129(1):191-198.e1.
13. Kurowska-Stolarska M, et al. IL-33 amplifies the polarization of alternatively activated macro-phages that contribute to airway inflammation. J Immunol. 2009;183(10):6469-6477.
14. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol. 2008;180(4):2443-2449.
15. Hung LY, et al. IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proc Natl Acad Sci USA. 2013;110(1):282-287.
16. Bonilla WV, et al. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science. 2012;335(6071):984-989.
17. Xu D, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA. 2008;105(31):10913-10918.
18. Beltrán CJ, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(7):1097-1107.
19. Kobori A, et al. Interleukin-33 expression is specif-ically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010;45(10):999-1007.
20. Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett. 2010;128(1):80-85.
21. Latiano A, et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One. 2013;8(4):e62144.
22. O'Donnell C, et al. An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. Br J Cancer. 2016;114(1):37-43.
23. Oboki K, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA. 2010;107(43):18581-18586.
24. Monticelli LA, Osborne LC, Noti M, Tran SV, Zaiss DM, Artis D. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA. 2015;112(34):10762-10767.
25. Groß P, Doser K, Falk W, Obermeier F, Hofmann C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis. 2012;18(10):1900-1909.
26. Gaudio E, et al. Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastruc-tural aspects. Dig Dis Sci. 1999;44(7):1458-1475.
27. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxy-methane and dextran sodium sulfate. Cancer Sci. 2003;94(11):965-973.
28. Bersudsky M, et al. Non-redundant properties of IL-1a and IL-1ß during acute colon inflammation in mice. Gut. 2014;63(4):598-609.
29. Waddell A, et al. IL-33 signaling protects from murine oxazolone colitis by supporting intestinal epithelial function. Inflamm Bowel Dis. 2015;21(12):2737-2746.
30. Schiering C, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513(7519):564-568.
31. Palm NW, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell. 2014;158(5):1000-1010.
32. Brandtzaeg P. Update on mucosal immunoglobu-lin A in gastrointestinal disease. Curr Opin Gas-troenterol. 2010;26(6):554-563.
33. Murthy AK, Dubose CN, Banas JA, Coalson JJ, Arulanandam BP. Contribution of poly-meric immunoglobulin receptor to regulation of intestinal inflammation in dextran sulfate sodium-induced colitis. J Gas troenterol Hepatol. 2006;21(9):1372-1380.
34. Mirpuri J, et al. Proteobacteria-specific IgA regulates maturation of the intestinal microbiota. Gut Microbes. 2014;5(1):28-39.
35. Coffman RL, Lebman DA, Shrader B. Trans-forming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med. 1989;170(3):1039-1044.
36. Elinav E, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011;145(5):745-757.
37. Normand S, et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcino-genesis upon injury. Proc Natl Acad Sci USA. 2011;108(23):9601-9606.
38. Man SM, et al. Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer. Cell. 2015;162(1):45-58.
39. Planer JD, et al. Development of the gut microbi-ota and mucosal IgA responses in twins and gno-tobiotic mice. Nature. 2016;534(7606):263-266.
40. Moon C, Baldridge MT, Wallace MA, Burnham CA, Virgin HW, Stappenbeck TS. Vertically transmitted faecal IgA levels determine extra-chromosomal phenotypic variation. Nature. 2015;521(7550):90-93.
41. Kau AL, et al. Functional characterization of IgA-targeted bacterial taxa from under-nourished Malawian children that produce diet-dependent enteropathy. Sci Transl Med. 2015;7(276):276ra24.
42. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004;54(pt 5):1469-1476.
43. Ijssennagger N, et al. Gut microbiota facilitates dietary heme-induced epithelial hyperprolifera-tion by opening the mucus barrier in colon. Proc Natl Acad Sci USA. 2015;112(32):10038-10043.
44. Kang CS, et al. Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dex-tran sulfate sodium-induced colitis. PLoS One. 2013;8(10):e76520.
45. Ings RM, McFadzean JA, Ormerod WE. The mode of action of metronidazole in Trichomonas vaginalis and other micro-organisms. Biochem Pharmacol. 1974;23(9):1421-1429.
46. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastro-enterology. 1999;116(5):1107-1114.
47. Atarashi K, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331(6015):337-341.
48. Elinav E, et al. NLRP6 inflammasome is a regulator of colonic microbial ecology and risk for colitis. Cell. 2011;145(5):745-757.
49. Lukens JR, et al. Dietary modulation of the microbiome affects autoinflammatory disease. Nature. 2014;516(7530):246-249.
50. Nielsen OH. New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne). 2014;1:3.
51. Maywald RL, et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci USA. 2015;112(19):E2487-E2496.
52. Coleman KM, Gudjonsson JE, Stecher M. Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1a, for the treatment of psoriasis. JAMA Dermatol. 2015;151(5):555-556.
53. Hong DS, et al. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15(6):656-666.
54. Levy M, et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell. 2015;163(6):1428-1443.
55. Chen GY, Liu M, Wang F, Bertin J, Núñez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol. 2011;186(12):7187-7194.
56. Palm NW, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell. 2014;158(5):1000-1010.
57. Zhang H, Sparks JB, Karyala SV, Settlage R, Luo XM. Host adaptive immunity alters gut micro-biota. ISME J. 2015;9(3):770-781.
58. Dingemanse C, et al. Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. Carcinogenesis. 2015;36(11):1388-1396.
59. Schneeberger M, et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep. 2015;5:16643.
60. Matsuki T, Nakae S, Sudo K, Horai R, Iwakura Y. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int Immunol. 2006;18(2):399-407.
61. Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol. 2010;185(8):4912-4920.
62. Zaki MH, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigen-esis. Cancer Cell. 2011;20(5):649-660.
63. Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S. Intestinal integrity and Akkerman-sia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol. 2007;73(23):7767-7770.
64. Malik A, Sharma D, St Charles J, Dybas LA, Mansfield LS. Contrasting immune responses mediate Campylobacter jejuni-induced colitis and autoimmunity. Mucosal Immunol. 2014;7(4):802-817.
65. Zhu Q, et al. Cutting edge: STING mediates protection against colorectal tumorigenesis by gov-erning the magnitude of intestinal inflammation. J Immunol. 2014;193(10):4779-4782.